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ABSTRACT
Background. Chronic kidney disease (CKD) is a recognized
global health problem. While some CKD patients remain stable
after initial diagnosis, others can rapidly progress towards end-
stage renal disease (ESRD). This makes biomarkers capable of
detecting progressive forms of CKD extremely valuable, espe-
cially in non-invasive bioﬂuids such as urine. Screening for
metabolite markers using non-targeted metabolomic techni-
ques like nuclear magnetic resonance spectroscopy is increas-
ingly applied to CKD research.
Methods. A cohort of CKD patients (n¼ 227) with estimated
glomerular ﬁltration rates (eGFRs) ranging from 9.4–130mL/
min/1.73 m2 was evaluated and urine metabolite proﬁles were
characterized in relation to declining eGFR. Nested in this cohort,
a retrospective subset (n¼ 57) was investigated for prognostic
metabolite markers of CKD progression, independent of baseline
eGFR. A transcriptomic analysis of murine models of renal fail-
ure was performed to validate selected metabolomic ﬁndings.
Results. General linear modeling revealed 11 urinary metabo-
lites with signiﬁcant associations to reduced eGFR. Linear mod-
elling speciﬁcally showed that increased urine concentrations of
betaine (P< 0.05) and myo-inositol (P< 0.05) are signiﬁcant
prognostic markers of CKD progression.
Conclusions. Renal organic osmolytes, betaine and myo-
inositol play a critical role in protecting renal cells from
hyperosmotic stress. Kidney tissue transcriptomics of murine
preclinical experimentation identiﬁed decreased expression of
Slc6a12 and Slc5a11 mRNA in renal tissue consistent with
defective tubular transport of these osmolytes. Imbalances in
renal osmolyte regulation lead to increased renal cell damage
and thus more progressive forms of CKD. Increases in renal
osmolytes in urine could provide clinical diagnostic and prog-
nostic information on CKD outcomes.
Keywords: CKD, disease progression, metabolomics, osmo-
lytes, transcriptomics, urine
INTRODUCTION
Chronic kidney disease (CKD) is a term used to include a
wide range of diseases that reduce kidney function. The
National Kidney Foundation defines CKD as 3 months of
kidney damage or an estimated glomerular filtration rate
(eGFR)<60mL/min/1.73 m2 [1]. Disease aetiology in CKD is
diverse, leading to variability in morbidity and mortality [2].
Further, not all populations have an equal risk for developing
CKD and progressing towards end-stage renal disease (ESRD);
therefore, high-risk populations with diabetes and/or hyperten-
sion should receive targeted testing for CKD [2]. eGFR can be
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation or the Modification of
Diet in Renal Disease (MDRD) study equation [1, 2]. However,
both measures are relatively insensitive in early stage CKD and
their prognostic value is limited.
Novel biomarkers that are more sensitive in early stage
CKD are needed for diagnosis and prognosis of CKD pro-
gression [3]. Metabolomics can analyse biofluids for specific
metabolic signatures reflecting CKD status [4], offering prom-
ising non-invasive methods to screen, diagnose and prognose
patients for CKD [5–7]. Mass spectrometry (MS) and nuclear
magnetic resonance (NMR) are the two main analytical plat-
forms used in metabolomics [8]. Here we use NMR spectro-
scopy as a quantitative state-of-the-art analytical platform
that is widely used in metabolome studies [9]. NMR can
detect a wide range of metabolites from various chemical
classes, delivering robust transferable data under optimized
conditions [10].
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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The purpose of this study was to use NMR-based metabolo-
mic strategies to elucidate novel urinary markers supportive of
current methods for diagnosing CKD. Urine samples from a
cohort of 227 patients in various stages of CKD were utilized.
An additional aim was to identify prognostic markers that indi-
cate patients at risk of CKD progression towards ESRD. A
nested retrospective subgroup (n¼ 57) from the cohort was
analysed using follow-up eGFR measurements and a calculated
rate of CKD progression.
Results of these analyses point to increased urine concentrations
of renal osmolytes as markers of reduced eGFR. These compounds
were also significantly elevated in the urine of CKD patients with
progressive forms of CKD. These metabolite data were supported
with messenger RNA (mRNA) data generated from independent
murine kidney fibrosis and injury experimentation.
MATERIALS AND METHODS
Study cohort and sampling
The cohort consisted of patients from the Nephrology
Outpatient Clinic at Ghent University Hospital, Ghent,
Belgium. Samples were collected in the period 17 January 2011
to 7 July 2015. eGFR was determined using the CKD-EPI equa-
tion. Important metadata used in the analysis can be found in
Table 1. Sample collection was performed in accordance with
local ethics requirements and in accordance with the current
revision of the Helsinki Declaration.
A total of 57 patients had sufficient follow-up data to moni-
tor their respective rate of CKD progression (i.e.3 eGFR
measurements, minimum of 2-years duration). To reduce con-
founding factors, only samples from patients with systemic dis-
eases or glomerular diseases were used, and patients with renal
transplantation or receiving renal replacement therapy were
not considered (Supplementary Table S1). The percent annual
eGFR slope change from baseline was calculated using the
following equation, an approach that has also been previously
applied [11]:
% annual eGFR slope ¼ linear coefficient
baseline eGFR
 100%
Sample preparation for NMR and instrumental protocol
Upon collection, urine samples were immediately centri-
fuged (20800 g for 10min), aliquoted per 1mL and stored at
80C. Following defrosting, a buffering approach designed for
NMR analysis in urine was applied [12]. This included a deute-
rium oxide phosphate buffer (1.5M PO4, pH 7.4; Armar
Chemicals, Leipzig, Germany) with potassium fluoride (KF,
300mM) and (trimethylsilyl)propionic acid (TSP, 0.1%).
Phosphate salts, KF and TSP were purchased from Sigma
Aldrich Chemie (Steinheim, Germany).
Urine samples were analysed on a Bruker 800-MHz spec-
trometer operating at 800.35MHz with a quadrupole inverse
cryogenic probe. A standard one-dimensional pulse sequence
[recycle delay (RD) 90, t1 90, tm 90, acquire FID] was
acquired, with water suppression irradiation during RD of 2 s,
mixing time (tm) set on 200ms and a 90 pulse set to 10.13 ls,
collecting 512 scans into 64 000 data points with a spectral
width of 12 ppm. All spectra were manually phased, baseline
corrected and calibrated to TSP (d 0.00) with TopSpin 3.2
(Bruker BioSpin, Rheinstetten, Germany). Data were imported
to MATLAB (MathWorks, Natick, MA, USA) and further proc-
essed, i.e., water and urea region removed (d 4.7–5.6). Daily
quality control samples (i.e. pooled urine sample) were meas-
ured throughout the cohort measurement to monitor instru-
ment performance, data processing (i.e. spectra pre-processing,
normalization and alignment) and metabolite stability.
The structural identity of metabolite compounds was deter-
mined by two-dimensional (2D) NMR methods; total correla-
tion spectroscopy (TOCSY) and heteronuclear single quantum
coherence (HSQC) spectroscopy. For 2D TOCSY spectra,
phase-sensitive and sensitivity-improved 2D TOCSY with
WATERGATE (3-9-19) and DIPSI-2 were acquired. For each
spectrum 19228  1024 data points were collected using 32
scans per increment, 16 dummy scans and 1 s acquisition time.
The spectral widths were set to 12 ppm for both the F1 and F2
dimensions. For 2D HSQC spectra, phase-sensitive ge-2D
HSQC using PEP and adiabatic pulses for inversion and refo-
cusing with gradients was used. Data points of 4788 1280 per
spectra were collected with 256 scans per increment, 16 dummy
scans and an acquisition time of 0.25 s. Spectral widths were set
to 12 ppm for the F2 and 230 ppm for F1.
NMR-based statistical tools
Data processing and statistics were performed in MATLAB
2015b, RStudio and the MetaboAnalyst platform (http://www.
metaboanalyst.ca) [13]. Probabilistic quotient normalization
[14] was used for normalization of spectral data to account for
biological variation in urine dilution. This method is an
improved normalization technique compared with single-
metabolite normalization [15], which is superior in the context
of CKD, as it avoids normalization to metabolites affected by
Table 1. Urine sample cohort (n¼ 227)
Male, n (%) 137 (60.4)
Age (years) 62.36 16.8 (17–88)
Disease groups (n, as deﬁned by
ERA-EDTA Primary Renal Disease Registry)
Tubulointerstitial diseases 35
Systemic diseases affecting the kidneya 96
Familial/hereditary nephropathies 23
Miscellaneous renal disorders 41
Glomerular diseases 32
Body mass index (kg/m2) 28.06 5.5 (16.3–47.9)
CKD stage (CKD-EPI, mL/min/1.73 m2), n
Stage 1 (eGFR >90) 25
Stage 2 (eGFR 89–60) 45
Stage 3 (eGFR 59–30) 115
Stage 4 (eGFR 29–15) 34
Stage 5 (eGFR <15) 8
eGFR (mL/min/1.73 m2) 516 25.7 (9.4–130)
This table provides an overview of cohort metadata used for biomarker discovery. Age,
gender, BMI and CKD disease groups were determined to be the most important meta-
data in linear modelling of metabolites. For age, BMI and eGFR, the mean and standard
deviation are shown with the range.
aSystemic diseases includes diabetes type 2 and hypertension.
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the disease. Spectral data were aligned using the recursive seg-
ment-wise peak alignment (RSPA) algorithm [16]. An orthogo-
nal partial least squares (OPLS) regression analysis [17] using
eGFR as the y variable was performed for spectral feature
selection. Spectral regions most affected by CKD display high
covariance and r2 values. Selected spectral features were struc-
turally identified using 2D NMR and matched with the human
metabolite database (HMDB) [18]. Identified metabolites
were quantified with the R-package BATMAN [19], measuring
the area under the curve. Data were then log transformed and
mean centered. General linear modelling was applied to each
identified metabolite with baseline eGFR or percent annual
eGFR slope as y variables, adjusted for age, gender, body mass
index (BMI) and disease group.
Kidney transcriptomics
Total RNA was isolated using the PureLink RNA Mini Kit
(Invitrogen, Paisley, UK). Affymetrix transcriptomics arrays of
kidney tissue (n¼ 3 control and n¼ 3 kidney injury, obtained
24 h after induction of kidney injury by a folic acid injection or
injection of vehicle) were performed at Unidad Geno´mica
Moncloa, Fundacio´n Parque Cientı´fico de Madrid, Madrid,
Spain, following the manufacturer’s protocol [20]. Image files
were initially obtained through Affymetrix GeneChip
Command Console software. Robust multichip analysis was
performed using the Affymetrix Expression Console software.
Starting from the normalized robust multichip analysis, the sig-
nificance analysis of microarrays was performed using the
limma package (Babelomics, http://www.babelomics.org), with
a false discovery rate (FDR) of 5% to identify genes significantly
dysregulated.
Experimental kidney injury
These studies were approved by the IIS-FJD animal ethics
committee and followed Directive 2010/63/EU on the protec-
tion of animals used for scientific purposes. For experimental
kidney injury, female 12- to 14-week-old C57/BL6 mice
received a single intraperitoneal injection of folic acid (Sigma
Aldrich) 250mg/kg in sodium bicarbonate 0.3mol/L (acute
kidney injury, n¼ 3) or a vehicle alone (controls, n¼ 3) and
were sacrificed 24 h later as previously described [20]. Kidneys
were cold saline perfused in situ before removal. One kidney
from each mouse was fixed in buffered formalin, embedded in
paraffin and stained with haematoxylin and eosin. The other
kidney was snap frozen in liquid nitrogen for ribonucleic acid
(RNA) studies. Samples from this experiment were used for
kidney transcriptomics. A second set of six mice per group with
folic acid nephropathy or vehicle-infused controls were proc-
essed in the same manner at 24 and 72 h following the induc-
tion of kidney injury and used for real-time quantitative
polymerase chain reaction (qPCR) validation.
Unilateral ureteral obstruction (UUO) was performed under
isoflurane-induced anaesthesia. The left ureter was ligated with
silk at two locations and cut to prevent urinary tract infection
(obstructed kidney) [21]. A total of five male 12- to 14-week-
old C57/BL6 mice were sacrificed 14 days after surgery. UUO
kidneys were compared with the healthy contralateral kidneys.
Real-time qPCR validation
Human metabolomics and murine transcriptomics results
were validated by real-time qPCR performed using mRNA
obtained from five UUO mice sacrificed on Day 14 and from
folic acid nephropathy mice vehicle-infused controls obtained at
24 and 72h following induction of kidney injury. RNA of 1mg
isolated by Trizol (Invitrogen) was reverse transcribed with a
High Capacity cDNA Archive Kit and real-time qPCR was per-
formed on a ABI Prism 7500 PCR system (Applied Biosystems,
Foster City, CA, USA) using the DDCt method [22]. Expression
levels are displayed as ratios to glyceraldehyde-3-phosphate
dehydrogenase. Pre-developed primer and probe assays were also
from Applied Biosystems.
Data mining
The Nephroseq [http://www.nephroseq.org/ (11 October
2017, date last accessed)] database was searched for human renal
biopsy transcriptomics data comparing patients with diverse
aetiologies of CKD with controls. The database was searched for
gene expression data for Slc5a11, Slc6a12 and Slc5A3.
Supplementary Figure S1 shows the experimental workflow.
RESULTS
Urine metabolite markers related to eGFR
An OPLS regression analysis of the entire cohort data set
measured by 1HNMR revealed spectral features with significant
linear relationship to eGFR (Figure 1). Spectral features with
the largest absolute covariance and r2 values (Figure 1C) were
targeted for identification and quantification (Figure 1A). A list
of the identified metabolites can be found in Supplementary
Table S2. General linear modelling of all quantified metabolites
showed 11 urinary metabolites having significant linear associa-
tions with eGFR, adjusted for age, gender, BMI and disease
group (Table 2). A positive association with decreased eGFR
reflects a decrease in the relative concentration of each respec-
tive metabolite as eGFR declines.
Metabolites from various metabolic pathways were altered
with reduced eGFR. Citric acid from the tricarboxylic acid cycle,
amino acids (e.g. threonine), lipid metabolism (e.g. ethanol-
amine), gut microbiome–derived uraemic toxins (e.g. indoxyl
sulphate and p-cresol sulphate), uracil and glycolic acid were
significantly lower with reduced eGFR. Many of these metabo-
lites have also been reported as significant markers of CKD
from previous studies [23–25], further strengthening them as
reliable biomarkers. Additionally, two metabolites,myo-inositol
and betaine, had negative coefficients, indicating a respective
urinary increase with reduced eGFR.
Metabolite markers related to CKD progression
A nested retrospective subgroup (n¼ 57) of the cohort was
analysed for urine metabolites predictive of CKD progression.
These CKD patients were well distributed throughout the range of
progression (r2¼ 0.96), which was from 5% per year (i.e. improve-
ment in eGFR) to 14.1% per year (i.e. strong deterioration)
(Supplementary Figure 2). The percent annual eGFR slope was
independent of baseline eGFR (P¼ 0.44) (Supplementary Figure
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S3). Linear modelling was again applied using the percent annual
eGFR slope change as the y variable. A total of eight metabolites
showed significant associations (Table 3). Citric acid, glycolic acid
and ethanolamine were again seen to be positively associated with
a declining percent annual eGFR slope. Creatinine and dimethyl-
amine were also positively associated. The highest b coefficients in
the modelling were seen for betaine and myo-inositol, which had
negative correlations (Figure 2). These osmolytes again showed
opposite trends from all other significant metabolites.
Due to the longitudinal nature of the sample group, the previ-
ously mentioned metabolites may act as prognostic urinary bio-
markers of CKD outcome.We focused on to examining the renal
osmolytes betaine and myo-inositol, as their respective trends
were contrary to the other metabolites and their physiological
relevance in kidney health is unique. Using receiver operating
characteristics (ROC) analysis, the values of betaine and myo-
inositol were examined in the first and last quartiles of the CKD
progression subgroup. Here, the first quartile (i.e. ‘stable’) showed
no CKD progression, with an eGFR change ofþ5% to 1% per
year. The last quartile (i.e. ‘rapid’ progression) showed an eGFR
change of 8% to 15% per year. The area under the curve
(AUC) of the ROC analysis for betaine was 0.814 and for myo-
inositol was 0.781. Combined, both betaine and myo-inositol
showed an AUC of 0.84 (Supplementary Figure S4).
Decreased kidney expression of betaine and myo-
inositol transporters in murine models
To determine if osmolyte transporters were a factor for
increased urine osmolyte concentrations, kidney transcriptom-
ics of a murine CKD model were analysed for gene expression
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FIGURE 1: OPLS regression analysis for feature selection in NMR spectra. (A) Sample spectrum with identiﬁed metabolites labelled: (1) 2-furoyl-
glycine, (2) 2-hydroxyisobutyric acid, (3) 3-hydroxyisovaleric acid, (4) 4-deoxyerythronic acid, (5) 4-deoxytheonic acid, (6) acetic acid, (7) acetone,
(8) trigonelline, (9) betaine, (10) cis-aconitic acid, (11) citric acid, (12) creatine, (13) creatinine, (14) D-glucose, (15) dimethylamine, (16) dimethly-
glycine, (17) ethanolamine, (18) formic acid, (19) fumaric acid, (20) glycine, (21) glycolic acid, (22) guanidoacetic acid, (23) pseudouridine, (24)
hippuric acid, (25) indoxyl sulfate, (26) L-acetylcarnitine, (27) L-alanine, (28) trimethylamine, (29) L-lactic acid, (30) L-phenylalanine, (31) L-
threonine, (32) trimethylamine-N-oxide, (33) L-tyrosine, (34) uracil, (35) myo-inositol, (36) N-methylnicotinamide, (37) p-cresol sulfate, (38) phe-
nylacetylglutamine, (39) phosphorylcholine, (40) p-hydroxyphenylacetic acid, (41) proline betaine, (42) succinic acid, (43) tartaric acid and (44)
taurine. (B) Loadings plot of OPLS regression analysis with eGFR in the y variable. This plot represents a ‘statistical’ pseudo-spectrum that displays
the OPLS model covariance on the y-axis and chemical shift on the x-axis. The colour bar represents the r2 value for that spectral region to eGFR.
Plots in (A) and (B) are aligned on the x-axis, which shows which spectral regions may best describe CKD-related changes and warrant structural
identiﬁcation. (C) Scores plot of the OPLS model showing data separation based on sample eGFR (colour bar).
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changes. The kidney gene expression of Slc5a3, Slc5a11 and
Slc6a12 (see Figure 3) was assessed by real-time qPCR in experi-
mental kidney fibrosis induced by UUO, a classic murine model
of renal fibrosis and inflammation that recapitulates all the key
events in CKD leading to fibrosis [26]. Significant downregula-
tion of the genes encoding the myo-inositol transporter
(Slc5a11) and the betaine transporter (Slc6a12) were observed
(Figure 4A).
The candidate genes (Slc5a3, Slc5a11, Slc6a12) tested in
experimental CKD were also observed in a transcriptomics
analysis of kidney injury using a murine model injected with
folic acid. Supplementary Table S3 shows all differentially
expressed genes in the transcriptomics array with a fold change
increasing or decreasing in expression>25% and FDR<5%, as
previously reported [27]. Our hypothesis-driven analysis of the
transcriptomics database identified decreased expression of
Slc6a12, Slc5a3 and Slc5a11 (Figure 4B). Downregulation of
these genes did not appear to result from the downregulation of
the transcription factor tonicity-responsive enhancer-binding
protein (TonEBP/NFAT5), a master regulator of osmolyte
transporters, since TonEBP/NFAT5 expression was
preserved (fold change 0.96, FDR¼ ns). Additionally, Myox,
the gene encodingmyo-inositol oxygenase, was also downregu-
lated in kidney injury (Supplementary Figure S5). Real-time
qPCR confirmed in an independent validation experiment of
the decreased expression of Slc5a3, Slc5a11 and Slc6a12 mRNA
at 24h of kidney injury induction and persisting after 72 h
(Figure 4C). These data suggest that these gene expression
changes are shared by both CKD and acute kidney injuries.
DISCUSSION
In the present study we investigated the urine metabolome
signatures of patients with CKD and CKD progression. Most
significant metabolites decrease in urinary concentration
with reduced eGFR and in patients with progressing CKD.
However, in these same patients we also observed significant
linear increases ofmyo-inositol and betaine. Both metabolites
had the highest absolute b coefficients in our modelling of
percent annual eGFR slope and showed prognostic value in
predicting patients who rapidly progress from those who
remained stable. Kidney transcriptomics identified defective
gene expressions of myo-inositol and betaine transporters in
Table 3. Signiﬁcant prognostic metabolites of CKD progression
Metabolite b SE P-value
Creatinine 0.059 0.011 3.57E-06
Citric acid 0.079 0.027 0.005
Ethanolamine 0.039 0.014 0.010
Betaine 0.153 0.057 0.010
Trimethylamine N-oxide 0.053 0.022 0.022
Dimethylamine 0.025 0.011 0.025
Glycolic acid 0.09 0.041 0.031
myo-Inositol 0.091 0.042 0.035
This table shows general linear modelling results for prognostic markers of CKD pro-
gression. These metabolites show signiﬁcant linear associations with percent annual
eGFR slope of the selected progression subset. The b coefﬁcient, standard error (SE) and
P-value of each metabolite are reported and are adjusted for age, gender, BMI and CKD
disease group A negative association (i.e. negative b) indicates an increase in the metab-
olite concentration as the percent annual eGFR slope decreases (i.e. CKD progression
rate increases).
Table 2. Signiﬁcant diagnostic metabolites of eGFR
Metabolite b SE P-value
Citric acid 0.023 0.003 3.42E-10
Uracil 0.02 0.004 3.25E-07
Formic acid 0.01 0.002 4.76E-05
L-threonine 0.016 0.005 3.15E-03
Ethanolamine 0.004 0.001 3.61E-03
myo-Inositol 0.014 0.005 6.12E-03
Glycolic acid 0.014 0.005 1.14E-02
Indoxyl sulphate 0.009 0.004 1.53E-02
Hippuric acid 0.011 0.004 1.57E-02
p-Cresol sulphate 0.014 0.006 3.03E-02
Betaine 0.013 0.006 4.79E-02
This table shows general linear modelling results for diagnostic markers of baseline
eGFR. These metabolites show signiﬁcant linear associations with eGFR. The b coefﬁ-
cient, standard error (SE) and P-value for each metabolite are reported and are adjusted
for age, gender, BMI and CKD disease group. Metabolites with a negative correlation
(i.e. negative b) indicate metabolites that have increased urinary concentration as eGFR
declines.
FIGURE 2: Plots of adjusted generalized linear model for renal osmolytes. A negative percent annual eGFR slope indicates patients that are
progressing in CKD. The linear model equation, 95% conﬁdence intervals and P-values are deﬁned in the legend.
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FIGURE 3: Function of gene products in tubular cells. Slc6a12 encodes the betaine transporter bgt-1. Slc5a3 encodes the sodiummyo-inositol
transporter Smit. Slc5a11 encodes the sodium myo-inositol transporter Smit2.Myox encodes myo-inositol oxygenase, which is involved inmyo-
inositol synthesis. Transcription factor TonEBP/Nfat5 regulates gene expression of all osmolyte transporter genes; (Slc6a11, Slc5a3, and Slc5a11).
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FIGURE 4: Gene expression data. (A) Changes in experimental kidney ﬁbrosis assessed by real-time qPCR. Kidney mRNA was measured 14 days
after induction of UUO leading to kidney ﬁbrosis. Obstructed kidneys were compared with contralateral unobstructed kidneys. (B) Changes in
experimental kidney injury transcriptomics. Kidney mRNA was measured 24 h after induction of kidney injury by a single injection of folic acid
and in vehicle-injected controls. (C) Changes in experimental kidney injury assessed by real-time qPCR. Kidney mRNA was measured 24 h and
72 h after induction of kidney injury by a single injection of folic acid and in vehicle-injected controls. *P 0.05, **P  0.01.
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murine kidney disease models, providing convincing evi-
dence that elevated osmolyte concentrations seen in the urine
are partially a result of perturbed renal osmolyte transport.
Figure 5 provides a proposed model of osmolyte dysregula-
tion during CKD. This may be the first demonstration
that links urinary osmolyte concentrations with clinical CKD
outcomes using a metabolomic analysis supported with
transcriptomics.
The osmolality of mammalian blood is normally kept con-
stant at 290 mosmol/kg [28] and maintained by regulatory
mechanisms such as the renin–angiotensin–aldosterone and
antidiuretic hormone systems. However, normal kidney func-
tion requires an interstitial osmotic gradient in renal medulla
four times that of plasma osmolality. The hyperosmotic condi-
tions created by NaCl and urea are required for urine concen-
tration. However, these conditions can be damaging to cells and
proteins [28, 29] and cause water to diffuse out of cells, resulting
in cellular shrinkage [30]. Osmolytes have evolved in renal tis-
sues as protective compounds against osmotic stress [31], and
studies have explored mechanisms for how osmolytes provide
protein stability [32, 33]. Five protective osmolytes are used in
renal cells: sorbitol, betaine, myo-inositol, taurine and glycero-
phosphocholine (GPC), with a large proportion being betaine
and myo-inositol [28, 29]. The concentrations of these osmo-
lytes are regulated through the TonEBP/NFAT5 transcription
factor [28, 34], which regulates the transcription of all
transporter proteins responsible for osmolyte uptake in renal
cells. This transcription factor is critical to kidney health and
has been proven essential in knockout models [30, 35].
Mechanisms for betaine uptake in medullary cells are well
studied [28, 36]. As osmolality increases, so too do medullary
betaine levels [28, 37]. Uptake comes primarily from extracellu-
lar sources and not from increased local cellular synthesis [28].
Betaine is freely filtered by glomeruli and actively reabsorbed by
renal tubules at levels >95% of the filtered load [38, 39]
(Figure 5A). Therefore, non-perturbed reabsorption mecha-
nisms for betaine should not allow for an increase in urinary
levels as seen in our study. The primary transporter of betaine
in medullary cells is betaine/GABA transporter 1 (Bgt-1)
[28, 40], which is encoded by the Slc6a12 gene and regulated
by TonEBP/NFAT5 [30]. Hypertonicity leads to increased
TonEBP/NFAT5 expression and localization of Bgt-1 to apical
and basolateral plasma membranes in tubular cells (Figure 5B).
It is estimated that betaine could account for 25% of the total
osmolyte content [40, 41], and a recent study found that betaine
ranked high in protein-stabilizing properties [32]. Its high
abundance and stabilizing properties provide evidence that
betaine is one of the more important organic osmolytes in
medullary tissues. A recent study of acute renal ischaemia found
kidney tissue had reduced levels of betaine and myo-inositol
when compared with controls [42, 43]. Therefore, increased
betaine in the urine most likely reflects CKD-related renal stress
FIGURE 5: Hypertonicity response mechanism in CKD. A proposed model of the osmolyte mechanism in CKD. (A)Model of osmolyte reab-
sorption in a healthy nephron. (B) Tubular cell response mechanism to increased hypertonicity in medullary tissue. (C) Blood and urine osmo-
lyte concentrations in response to hypertonicity. Patients with progressive forms of CKD have increased osmolyte concentrations in urine.
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(Figure 5C). Our data show an increase of betaine in human
urine during CKD, most likely due to Bgt-1 transporter
downregulation, given the lower gene expression in experimental
kidney fibrosis and injury. However, the release of osmolytes into
the urine following renal cell damage may also contribute.
Myo-inositol also increases in healthy medullary cells when
interstitial osmolality increases, and reducedMyox gene expres-
sion in experimental kidney injury argues against increased
local myo-inositol production being a major driver of higher
urinary levels in CKD. Sodium myo-inositol transporters (Smit
and Smit2) encoded by the Slc5a3 and Slc5a11 genes are pri-
marily responsible for renal myo-inositol uptake [28] and are
also regulated by TonEBP/NFAT5 [30]. Downregulation of
Slc5a11 was observed in experimental kidney fibrosis, and
Slc5a3 and Slc5a11 were also downregulated during kidney
injury, suggestive of a general decrease in myo-inositol uptake
capacity by stressed tubular cells. Furthermore, a recent study
found myo-inositol significantly elevated in the urine of mice
with renal vasculitis [44].
We hypothesize that increased urinary levels of renal osmo-
lytes reflect damage to kidney tissue from hyperosmolar stress,
especially in diseases such as diabetic and hypertensive nephrop-
athy, where osmotic and hypertensive stresses cause microvascu-
lature damage [35, 45]. In support, gene expression data of
osmolyte transporters point to a dysregulated transporter system
as a major factor of osmolytes lost into the urine. Data mining of
human kidney biopsy gene expression using the Nephroseq data-
base (www.Nephroseq.org) showed a study exploring gene
expression in human CKD with diverse aetiologies [46]. These
data identified the downregulated kidney expression of Slc5a11
(foldchange 3.15 discovery, 1.91 validation) and Slc6a12
(foldchange 1.63 discovery, 6.98 validation) mRNA in
human CKD kidneys compared with control kidneys. However,
no difference in Slc5a3 mRNA expression was observed, as was
similarly seen in our experimental kidney fibrosis data.
The present data are consistent with the increased recogni-
tion of osmotic stress as a driving force behind CKD progres-
sion. For example, repeated dehydration and osmotic stress are
thought to be a key driver of kidney injury in Meso-American
nephropathy patients [47]. Moreover, tolvaptan, an antagonist
of antidiuretic hormone receptors that promotes polyuria and
decreases medullary hyperosmolarity, has been recently
approved to treat polycystic kidney disease. Experimental evi-
dence suggests that tolvaptan or high water intake may be pro-
tective in other nephropathies [48]. Finally, data consistent with
impaired kidney responses to osmotic stress in CKD are in
line with clinical observations that CKD patients are more sen-
sitive to the toxic effects of high-osmolality iodinated contrast
media [49].
There are certain limitations in our study. The number of
samples in the CKD progression analysis is somewhat low, and
a larger, multicentre, validation study is warranted. However,
betaine and myo-inositol showed the same significant direction
of alteration in the larger-scale analysis of the total cohort
eGFR. Furthermore, gene expression data from independent
experimental murine models provides interdiscipline validation
of the pathophysiological feasibility of osmolyte abnormalities
acting as CKD progression biomarkers. Therefore, the
increased urinary output of betaine and myo-inositol reflects
abnormal tubular transport of osmolytes and an impaired renal
medullary response to osmotic stress in CKD progression.
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